Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Tonix Pharmaceuticals Holding's Business Segments
Tonix Pharmaceuticals Holding's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Tonmya
Total Revenue
$ 14
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Tonmya0%
- Zembrace Symtouch36.4%
- Tosymra6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Tonmya | $ 15 | - |
| Zembrace Symtouch | $ 5 | 36.4% |
| Tosymra | $ 1 | 6% |
Revenue by Product & Service Category - FY
- Tonmya80.9%
- Zembrace Symtouch14.7%
- Tosymra4.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Tonmya | $ 11 | 80.9% |
| Zembrace Symtouch | $ 2 | 14.7% |
| Tosymra | $ 1 | 4.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Tonmya0%
- Zembrace Symtouch36.4%
- Tosymra6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Tonmya | $ 15 | - |
| Zembrace Symtouch | $ 5 | 36.4% |
| Tosymra | $ 1 | 6% |
Description of Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company that aims to discover, develop, and commercialize innovative therapies for psychiatric and neurological disorders. The company is focused on the development of small molecules and biologics that modulate the physiological pathways responsible for these disorders.
One of the key therapeutic areas Tonix Pharmaceuticals is actively involved in is posttraumatic stress disorder (PTSD). The company has developed a proprietary formulation of cyclobenzaprine HCl, known as TNX-102 SL, which is currently in late-stage clinical development for the treatment of PTSD. TNX-102 SL is an orally disintegrating tablet that acts by selectively modulating sleep patterns and improving sleep quality, both of which are often disrupted in patients with PTSD.
In addition to PTSD, Tonix Pharmaceuticals is also dedicated to addressing other psychiatric and neurological conditions, including fibromyalgia and Alzheimer's disease. The company's pipeline includes multiple drug candidates targeted at these indications.
Tonix Pharmaceuticals actively pursues a unique approach to drug development called Precision Medicine, which involves identifying and targeting specific biomarkers associated with each disorder. By understanding the underlying biology of these disorders, the company aims to develop personalized therapies that have higher chances of success in clinical trials.
The company also places a strong emphasis on the use of innovative technologies in drug development. This includes leveraging advanced drug delivery systems, formulation technologies, and biomarker detection techniques to improve the efficacy, safety, and patient compliance of its therapies.
In terms of clinical development, Tonix Pharmaceuticals has established strategic collaborations with renowned academic institutions, research organizations, and contract research organizations (CROs). These partnerships allow the company to conduct rigorous clinical trials and access a wide range of scientific expertise and resources.
In terms of intellectual property, Tonix Pharmaceuticals has an extensive patent portfolio covering its drug candidates, formulations, and associated technologies. This provides the company with competitive advantages and protects its innovation from potential infringement.
Tonix Pharmaceuticals has an experienced management team and a strong scientific advisory board consisting of renowned experts in the field of neuropsychiatry and neurology. These individuals bring a wealth of industry knowledge and expertise, contributing to the company's strategic decision-making and drug development processes.
Furthermore, Tonix Pharmaceuticals has a sound financial position, with sufficient funding to support its ongoing clinical programs and business operations. The company has also secured grants and funding from various government agencies and industry partnerships to accelerate the development of its drug candidates.
Overall, Tonix Pharmaceuticals Holding Corp is a pioneering biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders. With its robust pipeline, strategic partnerships, and dedication to precision medicine, the company remains committed to bringing novel treatment options to patients in need.
One of the key therapeutic areas Tonix Pharmaceuticals is actively involved in is posttraumatic stress disorder (PTSD). The company has developed a proprietary formulation of cyclobenzaprine HCl, known as TNX-102 SL, which is currently in late-stage clinical development for the treatment of PTSD. TNX-102 SL is an orally disintegrating tablet that acts by selectively modulating sleep patterns and improving sleep quality, both of which are often disrupted in patients with PTSD.
In addition to PTSD, Tonix Pharmaceuticals is also dedicated to addressing other psychiatric and neurological conditions, including fibromyalgia and Alzheimer's disease. The company's pipeline includes multiple drug candidates targeted at these indications.
Tonix Pharmaceuticals actively pursues a unique approach to drug development called Precision Medicine, which involves identifying and targeting specific biomarkers associated with each disorder. By understanding the underlying biology of these disorders, the company aims to develop personalized therapies that have higher chances of success in clinical trials.
The company also places a strong emphasis on the use of innovative technologies in drug development. This includes leveraging advanced drug delivery systems, formulation technologies, and biomarker detection techniques to improve the efficacy, safety, and patient compliance of its therapies.
In terms of clinical development, Tonix Pharmaceuticals has established strategic collaborations with renowned academic institutions, research organizations, and contract research organizations (CROs). These partnerships allow the company to conduct rigorous clinical trials and access a wide range of scientific expertise and resources.
In terms of intellectual property, Tonix Pharmaceuticals has an extensive patent portfolio covering its drug candidates, formulations, and associated technologies. This provides the company with competitive advantages and protects its innovation from potential infringement.
Tonix Pharmaceuticals has an experienced management team and a strong scientific advisory board consisting of renowned experts in the field of neuropsychiatry and neurology. These individuals bring a wealth of industry knowledge and expertise, contributing to the company's strategic decision-making and drug development processes.
Furthermore, Tonix Pharmaceuticals has a sound financial position, with sufficient funding to support its ongoing clinical programs and business operations. The company has also secured grants and funding from various government agencies and industry partnerships to accelerate the development of its drug candidates.
Overall, Tonix Pharmaceuticals Holding Corp is a pioneering biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders. With its robust pipeline, strategic partnerships, and dedication to precision medicine, the company remains committed to bringing novel treatment options to patients in need.
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focusing on the development and commercialization of products for the treatment of various conditions, particularly those affecting the central nervous system (CNS), immune system, and other areas of unmet medical needs. Here is an extensive breakdown of the segments, products, and services they offer:
Segments
1. Central Nervous System (CNS) Disorders:
- Tonix is heavily invested in developing treatments for various CNS disorders, including pain, anxiety, mood disorders, and neurodegenerative conditions. This segment aims to address significant unmet needs in mental health and neurological health through innovative pharmacological approaches.
2. Immunology:
- The company is exploring therapies that modulate the immune response to treat autoimmune diseases, infectious diseases, and other immunological disorders. This segment seeks to utilize advanced drug formulation and delivery methods to enhance therapeutic efficacy.
3. Infectious Diseases:
- Tonix is involved in the development of preventative and therapeutic options for infectious diseases, leveraging its expertise in vaccine development and biological therapeutics.
Products
1. TNX-102 SL:
- A key candidate for the treatment of fibromyalgia and agitation related to Alzheimers disease. This product is an under-the-tongue formulation of cyclobenzaprine intended to enhance absorption and minimize side effects associated with oral administration.
2. TNX-1900:
- An investigational product aimed at treating chronic pain and migraine. It incorporates a unique approach to address pain signaling pathways and improve patient outcomes for chronic headache disorders.
3. TNX-601:
- A novel oral formulation of a well-known antidepressant intended for the treatment of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). It is designed to offer improved pharmacokinetic profiles and potentially reduce side effects.
4. TNX-2100:
- A formulation aimed at addressing immune-mediated diseases. This product is focused on enhancing immune response and is being considered for conditions that require modulation of the immune system.
5. Vaccines:
- Tonix is developing vaccine candidates, particularly in the realm of infectious diseases, harnessing advanced technologies and approaches to stimulate the immune response effectively.
Services
1. Clinical Development Services:
- Tonix engages in extensive clinical trials to ascertain the safety and efficacy of its products. This involves designing and implementing Phase I, II, and III trials, collaborating with various stakeholders including regulatory authorities and clinical research organizations (CROs).
2. Regulatory Affairs:
- The company actively collaborates with regulatory bodies such as the FDA to navigate the approval processes for its drug candidates. This includes compiling and presenting data necessary for Investigational New Drug applications (IND) and New Drug Applications (NDA).
3. Partnerships and Collaborations:
- Tonix often seeks partnerships with academic institutions, biotech firms, and pharmaceutical companies to enhance its research and development capabilities, share resources, and broaden its clinical reach.
4. Patient Engagement Programs:
- The company may implement initiatives to engage patients and healthcare providers throughout the clinical trial process, ensuring that the development programs align with patient needs and real-world applications.
5. Technology Transfer and Licensing:
- Tonix potentially engages in technology transfer agreements and licensing arrangements for its proprietary formulations and platforms, allowing broader access to their innovative drug delivery technologies.
Through these segments, products, and services, Tonix Pharmaceuticals aims to position itself at the forefront of therapeutic innovation, dedicated to addressing complex health challenges and improving the quality of life for patients suffering from various conditions.
Segments
1. Central Nervous System (CNS) Disorders:
- Tonix is heavily invested in developing treatments for various CNS disorders, including pain, anxiety, mood disorders, and neurodegenerative conditions. This segment aims to address significant unmet needs in mental health and neurological health through innovative pharmacological approaches.
2. Immunology:
- The company is exploring therapies that modulate the immune response to treat autoimmune diseases, infectious diseases, and other immunological disorders. This segment seeks to utilize advanced drug formulation and delivery methods to enhance therapeutic efficacy.
3. Infectious Diseases:
- Tonix is involved in the development of preventative and therapeutic options for infectious diseases, leveraging its expertise in vaccine development and biological therapeutics.
Products
1. TNX-102 SL:
- A key candidate for the treatment of fibromyalgia and agitation related to Alzheimers disease. This product is an under-the-tongue formulation of cyclobenzaprine intended to enhance absorption and minimize side effects associated with oral administration.
2. TNX-1900:
- An investigational product aimed at treating chronic pain and migraine. It incorporates a unique approach to address pain signaling pathways and improve patient outcomes for chronic headache disorders.
3. TNX-601:
- A novel oral formulation of a well-known antidepressant intended for the treatment of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). It is designed to offer improved pharmacokinetic profiles and potentially reduce side effects.
4. TNX-2100:
- A formulation aimed at addressing immune-mediated diseases. This product is focused on enhancing immune response and is being considered for conditions that require modulation of the immune system.
5. Vaccines:
- Tonix is developing vaccine candidates, particularly in the realm of infectious diseases, harnessing advanced technologies and approaches to stimulate the immune response effectively.
Services
1. Clinical Development Services:
- Tonix engages in extensive clinical trials to ascertain the safety and efficacy of its products. This involves designing and implementing Phase I, II, and III trials, collaborating with various stakeholders including regulatory authorities and clinical research organizations (CROs).
2. Regulatory Affairs:
- The company actively collaborates with regulatory bodies such as the FDA to navigate the approval processes for its drug candidates. This includes compiling and presenting data necessary for Investigational New Drug applications (IND) and New Drug Applications (NDA).
3. Partnerships and Collaborations:
- Tonix often seeks partnerships with academic institutions, biotech firms, and pharmaceutical companies to enhance its research and development capabilities, share resources, and broaden its clinical reach.
4. Patient Engagement Programs:
- The company may implement initiatives to engage patients and healthcare providers throughout the clinical trial process, ensuring that the development programs align with patient needs and real-world applications.
5. Technology Transfer and Licensing:
- Tonix potentially engages in technology transfer agreements and licensing arrangements for its proprietary formulations and platforms, allowing broader access to their innovative drug delivery technologies.
Through these segments, products, and services, Tonix Pharmaceuticals aims to position itself at the forefront of therapeutic innovation, dedicated to addressing complex health challenges and improving the quality of life for patients suffering from various conditions.